Medication info
Aicitameteu X-R Controlled-Release Tablet 50/1000 mg

Aicitameteu X-R Controlled-Release Tablet 50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Anguk Pharmaceutical Co., Ltd.
Appearance
A bright green, oval tablet with a convex surface on both sides, coated with a controlled-release film
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202202029 · Approved 2022.05.13 · Insurance code 650205960

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken with a meal once daily, preferably in the evening, with gradual dose escalation. To maintain its extended-release properties, swallow this medication whole; do not split, crush, grind, or chew it. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no prior history of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be gradually increased up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication. 2. Patients being treated with metformin: - The recommended initial total daily dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at their current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medication 50/1000 mg extended-release once daily. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medication is sitagliptin 100 mg. The initial dose of metformin should be based on the patient's blood glucose level and current dose. The dose should be gradually increased to reduce gastrointestinal adverse reactions caused by metformin. When this medication is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medication should be discontinued immediately.

Ingredients

Manufacturer
Anguk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to assist in blood sugar control in patients with type 2 diabetes in conjunction with dietary and exercise regimens. The combination of sitagliptin and metformin effectively manages blood sugar levels, improving diabetes symptoms. Therefore, it is an appropriate treatment option for type 2 diabetes patients who require blood sugar control.

How to take

Adult dose

The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken with a meal once daily, preferably in the evening, with gradual dose escalation. To maintain its extended-release properties, swallow this medication whole; do not split, crush, grind, or chew it. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no prior history of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be gradually increased up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication. 2. Patients being treated with metformin: - The recommended initial total daily dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at their current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medication 50/1000 mg extended-release once daily. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medication is sitagliptin 100 mg. The initial dose of metformin should be based on the patient's blood glucose level and current dose. The dose should be gradually increased to reduce gastrointestinal adverse reactions caused by metformin. When this medication is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medication should be discontinued immediately.

Precautions

This medication contains sitagliptin and metformin, which are used in the treatment of diabetes. Firstly, severe allergic reactions may occur when taking this medication, so if symptoms such as rash, difficulty breathing, or swelling of the face or lips occur, use should be stopped immediately and a doctor should be consulted. Additionally, there is a risk of pancreatitis, which is inflammation of the pancreas, so if abdominal pain, vomiting, or severe abdominal discomfort is experienced, medical attention should be sought immediately. This medication should not be administered to patients with severely compromised renal function, acute heart disease, or severe infection, and if these conditions are suspected, consultation with a healthcare provider is essential. Use of iodinated contrast agents requires temporary discontinuation of this medication before and after the examination. Resumption of use should occur only after renal function is confirmed to be normal. It is advisable for women who are pregnant, may become pregnant, or are breastfeeding to avoid taking this medication for safety. When taking this medication, be vigilant for symptoms of hypoglycemia, especially when taken in conjunction with insulin or other blood sugar-lowering agents, as the risk of hypoglycemia may increase, and consulting a doctor if symptoms arise is recommended. Additionally, there is a rare but serious risk of lactic acidosis; therefore, if symptoms such as fatigue, muscle pain, difficulty breathing, abdominal pain, or weakness occur, seek medical attention immediately and discontinue use. This medication may affect liver and kidney function, so regular blood tests and kidney function evaluations are necessary, particularly in elderly patients or those with compromised renal function. Alcohol may increase the risks associated with this medication, so avoidance of alcohol during therapy is advisable. If undergoing surgery, this medication should be discontinued 48 hours prior to the procedure and resumed only after kidney function returns to normal postoperatively. Ultimately, it is important to maintain a consistent diet and exercise regimen while taking this medication, and regular monitoring of blood sugar levels and health status is crucial.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
Show 21 more
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • severe arthralgia
  • bullous pemphigoid
  • hypoglycemia
  • anemia
  • decreased serum vitamin B12

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, with storage temperatures maintained between 1 and 30 degrees Celsius. Proper storage ensures the effectiveness and safety of the medication.

Appearance and packaging

Appearance

A bright green, oval tablet with a convex surface on both sides, coated with a controlled-release film

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.